Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
949
Recruiting, any sponsor type, condition "non-small cell lung cancer"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting949
- Completed2,509
949 trials
Showing 1 to 25, recently updated first.
- Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT07388524 · 336 participants (planned) · Start Mar 2, 2027 · Primary completion Sep 30, 2032
Drug: Atezolizumab; Atezolizumab and Recombinant Human Hyaluronidase · For: Lung Non-Small Cell Carcinoma
Sites: Anaheim, California; Baldwin Park, California; Bellflower, California · 171 sites in all
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT06498635 · 306 participants (planned) · Start Apr 1, 2025 · Primary completion Jul 15, 2039
Drug: Durvalumab · For: Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8 and 1 more
Sites: Jonesboro, Arkansas; Beverly Hills, California; Dublin, California · 287 sites in all
PfizerPfizer (PFE)
NCT07227298 · 162 participants (planned) · Start Jan 30, 2026 · Primary completion Mar 8, 2029
Drug: PF-08634404; Sigvotatug Vedotin and 1 more · For: Advanced/Metastatic Non-Small Cell Lung Cancer; Carcinoma, Non-Small Cell Lung; Non-Small Cell Lung Cancer
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 108 sites in all
National Cancer Institute (NCI)NIH
NCT02133196 · 85 participants (planned) · Start Oct 23, 2014 · Primary completion Oct 23, 2027
Drug: Aldesleukin; Fludarabine and 2 more · For: Advanced Non-Small Cell Lung Cancer; Squamous Cell Carcinoma; Advanced NSCLC and 2 more
Sites: Bethesda, Maryland
- A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)Recruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07140016 · 40 participants (planned) · Start Sep 22, 2025 · Primary completion Dec 31, 2029
Drug: gilteritinib · For: Non-small Cell Lung Cancer (NSCLC); Anaplastic Lymphoma Kinase (ALK) Positive
Sites: Fullerton, California; Orange, California; Edwards, Colorado · 17 sites in all
Whitehawk Therapeutics, Inc.Industry
NCT07444814 · 226 participants (planned) · Start Dec 19, 2025 · Primary completion Sep 2028
Drug: HWK-007 · For: Endometrial Cancer; Ovarian Cancer; Ovarian Cancer Metastatic and 4 more
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 17 sites in all
IDEAYA BiosciencesIndustry
NCT07277413 · 570 participants (planned) · Start Mar 4, 2026 · Primary completion Apr 30, 2028
Drug: IDE892; IDE397 and 1 more · For: Bladder Cancer; Mesothelioma; Pleural Mesothelioma and 5 more
Sites: Goodyear, Arizona; Phoenix, Arizona; Duarte, California · 26 sites in all
PfizerPfizer (PFE)
NCT07489066 · 120 participants (planned) · Start Jun 30, 2026 · Primary completion Jul 29, 2028
Drug: PF-08634404; Chemotherapy Regimen 1 and 1 more · For: Carcinoma; Non-Small-Cell Lung; Lung Cancer (NSCLC) and 6 more
Sites: Huntsville, Alabama; Stanford, California; Athens, Georgia · 66 sites in all
- Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsPivotal-lookingRecruiting
Olema Oncology, Inc.Industry
NCT06784193 · 180 participants (planned) · Start Dec 16, 2024 · Primary completion May 30, 2027
Drug: OP-3136; Fulvestrant and 1 more · For: Advanced or Metastatic ER+ HER2- Breast Cancer (mBC); Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC); Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC) and 3 more
Sites: Gilbert, Arizona; Aurora, Colorado; Sarasota, Florida · 25 sites in all
- Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07222566 · 1,410 participants (planned) · Start Jan 6, 2026 · Primary completion Feb 27, 2029
Drug: PF-08634404; Pembrolizumab and 2 more · For: Advanced Non-Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung and 3 more
Sites: Bullhead City, Arizona; Chandler, Arizona; Gilbert, Arizona · 560 sites in all
National Cancer Institute (NCI)NIH
NCT03191149 · 46 participants (planned) · Start Apr 25, 2018 · Primary completion Jun 30, 2027
Drug: Osimertinib · For: Advanced Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IIIB Lung Non-Small Cell Cancer AJCC v7 and 1 more
Sites: Anchorage, Alaska; Fairbanks, Alaska; Fort Smith, Arkansas · 347 sites in all
Kestrel Therapeutics, Inc.Academic, hospital or other
NCT07458347 · 545 participants (planned) · Start Apr 21, 2026 · Primary completion Apr 2028
Drug: KST-6051; Gemcitabine/nab-paclitaxel and 6 more · For: KRAS-mutant Non-small Cell Lung Cancer (NSCLC); KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC); KRAS-mutant Colorectal Cancer (CRC) and 1 more
Sites: Los Angeles, California; Sarasota, Florida; Tampa, Florida · 9 sites in all
Haihua YuanAcademic, hospital or other
NCT07631884 · 15 participants (planned) · Start May 12, 2026 · Primary completion Dec 31, 2028
Drug: Trastuzumab Rezetecan · For: Solid Tumors; Neoplasms (Cancer / Tumors); Advanced Malignant Solid Neoplasm and 13 more
Sites: Shanghai, China
Voronoi, IncIndustry
NCT07699328 · 315 participants (planned) · Start Mar 26, 2024 · Primary completion Jan 1, 2029
Drug: VRN110755 · For: EGFR-Mutant Non-Small Cell Lung Cancer
Sites: Bedford Park, Australia; Clayton, Australia; Toronto, Canada · 29 sites in all
Wayshine Biopharm, Inc.Industry
NCT06868485 · 40 participants (planned) · Start Aug 18, 2025 · Primary completion Sep 30, 2027
Drug: WSD0922-FU Tablets, Dose level A; WSD0922-FU Tablets, Dose level B · For: Non Small Cell Lung Cancer
Sites: Weston, Florida; Manahawkin, New Jersey; Teaneck, New Jersey · 16 sites in all
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung CancerPivotal-lookingRecruiting
Verastem, Inc.Industry
NCT07659782 · 105 participants (planned) · Start Jul 22, 2026 · Primary completion Jun 2027
Drug: VS-7375 · For: Non-Small Cell Lung Cancer
Sites: Scottsdale, Arizona; Los Angeles, California; Aurora, Colorado · 27 sites in all
- A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D MutationPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07566052 · 356 participants (planned) · Start Aug 19, 2026 · Primary completion Jun 30, 2030
Drug: Setidegrasib; Docetaxel · For: Non-small Cell Lung Cancer (NSCLC)
Sites: Glendale, California; Los Angeles, California; San Francisco, California · 38 sites in all
National Cancer Institute (NCI)NIH
NCT06066138 · 30 participants (planned) · Start Nov 4, 2025 · Primary completion Jan 31, 2027
Drug: Atezolizumab · For: Locally Advanced Alveolar Soft Part Sarcoma; Metastatic Alveolar Soft Part Sarcoma; Locally Advanced Non Small Cell Lung Cancer and 7 more
Sites: Bethesda, Maryland
- Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung CancerPivotal-lookingRecruiting
Second Xiangya Hospital of Central South UniversityAcademic, hospital or other
NCT05979818 · 118 participants (planned) · Start Nov 13, 2024 · Primary completion Oct 31, 2028
Drug: Propranolol hydrochloride; Sintilimab and 3 more · For: Non Small Cell Lung Cancer; Propranolol; Immune Checkpoint Inhibitors and 4 more
Sites: Changsha, China · 4 sites in all
VA Office of Research and DevelopmentFederal agency
NCT05467748 · 66 participants (planned) · Start Dec 8, 2025 · Primary completion Dec 8, 2027
Drug: Tulmimetostat · For: Non Small Cell Lung Cancer
Sites: Long Beach, California; Sacramento, California; San Diego, California · 5 sites in all
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsPivotal-lookingRecruiting
Arvinas Inc.Industry
NCT07749586 · 499 participants (planned) · Start Jul 29, 2026 · Primary completion Mar 31, 2031
Drug: ARV-6723; Pembrolizumab and 1 more · For: Advanced Solid Tumor
Sites: Boston, Massachusetts; New York, New York; Huntersville, North Carolina · 5 sites in all
- Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7Pivotal-lookingRecruiting
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
NCT04613596 · 626 participants (planned) · Start Dec 2, 2020 · Primary completion Oct 31, 2028
Drug: Adagrasib; Adagrasib and 3 more · For: Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer
Sites: Goodyear, Arizona; Prescott Valley, Arizona; Safford, Arizona · 776 sites in all
Sichuan Cancer Hospital and Research InstituteAcademic, hospital or other
NCT07775040 · 43 participants (planned) · Start Aug 24, 2026 · Primary completion Jun 30, 2030
Drug: Tislelizumab; Carboplatin and 3 more · For: Non-Small Cell Lung Cancer
Sites: Chengdu, China
- A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07488676 · 150 participants (planned) · Start May 4, 2026 · Primary completion Jul 31, 2029
Drug: ASP546C · For: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma; Pancreatic Adenocarcinoma
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 35 sites in all
TRIANA Biomedicines, Inc.Industry
NCT07491497 · 160 participants (planned) · Start Mar 11, 2026 · Primary completion May 31, 2029
Drug: TRI-611 · For: ALK-positive NSCLC; ALK-Positive Lung Cancer; ALK-positive Non-small Cell Lung Cancer
Sites: San Francisco, California; Aurora, Colorado; Boston, Massachusetts · 20 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.